Literature DB >> 26434630

Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer.

Min Hu1, Kai Li1, Ninu Maskey1, Zhigao Xu1, Fang Yu1, ChunWei Peng2, Yan Li2, Guifang Yang3.   

Abstract

Chemokine receptor, CXCR3, has been increasingly reported to be involved in tumorigenesis and tumor progression, but limited data are available regarding the expression of CXCR3 in gastric cancer (GC). In the present study, the expressions of CXCR3 and its variants were detected in 96 GC and corresponding nontumor gastric tissues by immunohistochemical staining, in 40 freshly frozen GC and nontumor gastric tissues by reverse-transcription polymerase chain reaction and quantitative real-time polymerase chain reaction, and in 10 freshly frozen GC and nontumor gastric tissues by Western blotting. Results revealed that an overexpression of CXCR3 occurs in GC tissues as compared to the nontumor gastric tissues. High level of CXCR3 expression was found to be inversely associated with invasion depth and metastasis (P = .030 and P = .019, respectively) and directly associated with improved overall survival (log-rank test, P < .001). Furthermore, multivariate analysis showed that high CXCR3 expression acts an independent prognostic factor for GC patients (hazard ratio, 0.379 [0.196-0.734]; P = .004). The messenger RNA expression of both the CXCR3 variants, CXCR3-A and CXCR3-B, were up-regulated in GC tissues (P = .006 and P = .002, respectively), although CXCR3-B messenger RNA expression was significantly higher than CXCR3-A, with an average CXCR3-B to CXCR3-A ratio of 1.80. CXCR3-B protein expression was also up-regulated in GC tissues (P = .023). In conclusion, our study suggested a potential use of CXCR3 overexpression as a prognostic marker for GC and involvement of the up-regulation of CXCR3-B in favorable prognosis of GC patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CXCR3; CXCR3-B; Gastric cancer; Metastasis; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26434630     DOI: 10.1016/j.humpath.2015.08.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

Authors:  Fausto Petrelli; Rosa Berenato; Luca Turati; Alessia Mennitto; Francesca Steccanella; Marta Caporale; Pierpaolo Dallera; Filippo de Braud; Ezio Pezzica; Maria Di Bartolomeo; Giovanni Sgroi; Vincenzo Mazzaferro; Filippo Pietrantonio; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

2.  Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  Zhaoyan Qiu; Yi Chu; Bing Xu; Qian Wang; Mingzuo Jiang; Xiaowei Li; Gang Wang; Pengfei Yu; Guoxiao Liu; Hua Wang; Huijie Kang; Jiayu Liu; Yu Zhang; Jian-Ping Jin; Kaichun Wu; Jie Liang
Journal:  Oncotarget       Date:  2017-05-09

3.  Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR).

Authors:  K Boyé; C Billottet; N Pujol; I D Alves; A Bikfalvi
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 4.  Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.

Authors:  Li-Jun Xue; Xiao-Bei Mao; Li-Li Ren; Xiao-Yuan Chu
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

5.  CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.

Authors:  Yang Zhang; Linjuan Xu; Minggang Peng
Journal:  Onco Targets Ther       Date:  2018-02-27       Impact factor: 4.147

6.  The role of CXCR3/LRP1 cross-talk in the invasion of primary brain tumors.

Authors:  Kevin Boyé; Nadège Pujol; Isabel D Alves; Ya-Ping Chen; Thomas Daubon; Yi-Zong Lee; Stephane Dedieu; Marion Constantin; Lorenzo Bello; Marco Rossi; Rolf Bjerkvig; Shih-Che Sue; Andreas Bikfalvi; Clotilde Billottet
Journal:  Nat Commun       Date:  2017-11-17       Impact factor: 14.919

7.  The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells.

Authors:  Namita Kundu; Xinrong Ma; Regine Brox; Xiaoxuan Fan; Tyler Kochel; Jocelyn Reader; Nuska Tschammer; Amy Fulton
Journal:  Breast Cancer (Auckl)       Date:  2019-10-03

8.  Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu.

Authors:  Ninu Maskey; Niresh Thapa; Muna Maharjan; Girishma Shrestha; Narayani Maharjan; Hongbing Cai; Shangqin Liu
Journal:  Cancer Manag Res       Date:  2019-08-14       Impact factor: 3.989

9.  BioTarget: A Computational Framework Identifying Cancer Type Specific Transcriptional Targets of Immune Response Pathways.

Authors:  Tham H Hoang; Yue Zhao; Yiu Lam; Stephanie Piekos; Yueh-Chiang Han; Cameron Reilly; Pujan Joshi; Seung-Hyun Hong; Chang Ohk Sung; Charles Giardina; Dong-Guk Shin
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.379

10.  Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?

Authors:  Soledad Urra; Martin C Fischer; José R Martínez; Loreto Véliz; Paulina Orellana; Antonieta Solar; Karen Bohmwald; Alexis Kalergis; Claudia Riedel; Alejandro H Corvalán; Juan C Roa; Rodrigo Fuentealba; C Joaquin Cáceres; Marcelo López-Lastra; Augusto León; Nicolás Droppelmann; Hernán E González
Journal:  Oncotarget       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.